National Health Research Institutes

Pele Choi-Sing Chong

Chih-Hsiang Leng

Hsin-Wei Chen

Shih-Jen Liu

Ming-Hsi Huang

Yen-Hung Chow

Hsueh-Hung Liu

Chi-Ling Tseng

Chiung-Yi Huang

Shih-Yang Hsieh

Yu-Fen Tseng

Yu-Shuan Chen

Min-Shi Lee

Kuang-Nan Hsiao

Charles Dwo-Yuan Sia

Yan Chak Kwok

Chang-Ling Lin

Ray Jui-Yuan Chang

Meng-Shin Kuo

Chia-Chyi Liu

Li-Tzu Wang

Hsin-Yu Chen

Shu-Ching Hsu

Jui-Hsin Huang

Yueh-Liang Tsou

A composition in a water-in-oil-in-water (W/O/W) emulsion is disclosed. The composition comprises: (a) a continuous aqueous phase, comprising HO; (b) an oil phase or an oil shell, dispersed in the continuous aqueous phase; and (c) a hydrophilic polymer, stabilizing an interface between the continuous aqueous phase and the oil phase or the oil shell to form the water-in-oil-in-water (W/O/W) emulsion. The oil phase or the oil shell comprises: (i) oil; (ii) an internal aqueous phase, dispersed within the oil or the oil shell; and (iii) a lipophilic sorbitan-polyester conjugate, stabilizing an interface between the oil and the inner aqueous phase to form a water-in-oil (W/O) emulsion. The lipophilic sorbitan-polyester conjugate comprises: (1) sorbitan; and (2) poly(lactide-co-&#x3b5;-caprolactone) or polylactic acid (polylactide), conjugated to the sorbitan.

Sorbitan polyester conjugates for stabilizing water-in-oil emulsions and delivering controlled release of bioactive agents

The present invention relates to a recombinant adenoviral vector for generating immunity against enterovirus infection. In one embodiment, the recombinant adenoviral vector of the invention comprises an expression cassette encoding a PI protein and a 3 CD protease of an enterovirus. In another embodiment, the recombinant adenoviral vector of the invention comprises an expression cassette encoding a 3C protease or a 3CD protease of an enterovirus. The present invention also relates to a vaccine composition comprising the recombinant adenoviral vector as described. A method of inducing an immune response in a subject against enterovirus infection using the recombinant adenoviral vector and the vaccine composition is provided. Further provided is a method for producing virus like particles of an enterovirus by expressing the adenoviral vector as described herein in mammalian cells.

Adenoviral vector-based vaccine against enterovirus infection

Described herein are isolated polypeptides each containing one or more receptor-binding sites of toxin A (tcdA) of(Cd), nucleic acids encoding the polypeptides, and methods of using the polypeptides and nucleic acids.

Compositions and methods for treating clostridium difficile-associated diseases

This invention relates to an immunosuppressive cell, and methods of obtaining the cell and using the cell. The immunosuppressive cell is obtained by culturing a precursor cell in a medium that contains a GRO chemokine.

Immunosuppressive cells and methods of making and using thereof

Disclosed are methods of producing a purified EV71 virus antigen. Also disclosed are related immunogenic compositions and immunization methods.

Immunogenic compositions and uses thereof

A method of producing a recombinant lipidated polypeptide in. The method includes providing anhost cell adapted to express a recombinant lipidated polypeptide; and culturing thehost cell in a minimal medium under conditions that allow expression of the polypeptide in lipidated form.

Method of producing lipidated polypeptides

A method for preparing and purifying recombinant lipoprotein Ag473 of(NM) group B isolates. The method can be used in large-scale production of vaccines for(NM) group B.

[object Object]

This invention relates to, inter alia, an isolated lipidated polypeptide including a lipid moiety at the N-terminus and a plurality of epitopes, and methods of making and using the polypeptide.

Lipidated polyepitope vaccines

Disclosed are polypeptides and fusion proteins. Also disclosed are related immunotherapeutic compositions and methods.

Lipidated tumor-associated antigens and immunotherapeutic compositions

Disclosed are lipopeptides or lipoproteins, related compositions, and related methods.

Adjuvants

An immunopeptide containing a T cell epitope from the tumor associated antigen L6 (TAL6) and a nucleic acid encoding the immunopeptide are described herein. The immunopeptide or its encoding nucleic acid can be used as a component of an immune composition for enhancing immune response against cancer cells that express TAL6.

Immunogenic peptides of tumor associated antigen L6 and uses thereof in cancer therapy

A chimeric viral particle that comprises a RV fusion gene is disclosed. The RV fusion gene comprises a first nucleotide sequence encoding a RV that is devoid of RV E1 protein, and a second nucleotide sequence that linked in translation frame to the first nucleotide sequence and encodes a humoral immunogenic viral protein. The chimeric viral particle is free of RV E1 protein-encoding gene. A virus packaging cell that generates the chimeric viral particle comprising a RV fusion gene and an isolated expression vector comprising a RV fusion gene linked in translation frame to a promoter are also disclosed.

Polyvalent chimeric rubella virus-based vaccines

A method for enhancing a body's response to an immunogen is disclosed. The method comprises immunizing a subject in need thereof a vaccine composition in a water-in-oil (W/O/W) emulsion that comprises (a) an antigen; and (b) an adjuvant composition in a W/O/W emulsion. The adjuvant composition comprises: (i) a continuous aqueous phase comprising HO; (ii) an oil phase comprising oil dispersed in the continuous aqueous phase, comprising an internal aqueous phase comprising HO, being dispersed in the oil phase; and a physiologically acceptable lipophilic emulsifier selected from the group consisting of mannide monooleate and sorbitan esters, stabilizing the interface between the inner aqueous phase and the oil phase to form a water-in-oil (W/O) emulsion; and (iii) poly(ethylene glycol)-block-poly(lactide-co-&#x3b5;-caprolactone), stabilizing the interface between the oil phase and the continuous aqueous phase.

Multi-phase emulsions based on amphiphilic block copolymers

Production of a lipidated protein in anstrain adapted to membrane protein expression.

Disclosed are immunogenic composition, fusion proteins, and related methods for inducing immune response to dengue virus infection.

Growing community of inventors

Miaoli County, Taiwan

Pele Choi-Sing Chong